Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740138 | 0.80 | BRD4 (0.43) | KDM4EALDH1A1NPC1HPGDRAB9A | |
| SCHEMBL16631766 | 0.79 | NAPRT (0.49) | MCL1KDM4EALDH1A1NPC1HPGD | |
| SCHEMBL1080850 | 0.74 | PIN1 (0.47) | KDM4EALDH1A1NPC1HPGDRAB9A | |
| SCHEMBL27327925 | 0.73 | MCL1 (0.60) | MCL1KDM4EALDH1A1RAB9AALOX15 | |
| Hydrochloric Acid SCHEMBL6861539 | 0.73 | PIN1 (0.46) | KDM4EALDH1A1NPC1HPGDRAB9A | |
| SCHEMBL1759786 | 0.72 | MCL1 (0.64) | MCL1KDM4EALDH1A1ALOX15TSHR | |
| SCHEMBL14692514 | 0.72 | KMO (0.55) | KDM4EALDH1A1NPC1RAB9APIN1 | |
| SCHEMBL4884772 | 0.71 | TSHR (0.39) | MCL1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL18035933 | 0.70 | PDE2A (0.60) | HPGDPIN1GAAMAPTCYP1A2 | |
| SCHEMBL6509907 | 0.69 | ALOX15 (0.67) | MCL1KDM4EALDH1A1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2947082-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| US-9139587-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2676958-B1 | N1-Pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER (US) | 2015-07-01 | — | — | EP | disclosed |
| CN-102695708-B | N1-pyrazolospiroketone acetyl-coA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-15 | — | — | CN | disclosed |
| US-20140288111-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8802690-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2676958-A1 | N1-Pyrazolospiroketone acetyl-CoA carboxylase inhibitors | Pfizer Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2499139-B1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130296319-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-8507681-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130030181-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8288405-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2499139-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2499140-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225900-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2011058473-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058474-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288111-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, PC, ACACB | MCL1 4407/4885KDM4E 1385/4885ALDH1A1 164/4885 |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | MCL1 4407/4885KDM4E 1385/4885ALDH1A1 164/4885 |
| US-20130296319-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, PC, ACACB | MCL1 4366/4885KDM4E 1311/4885ALDH1A1 161/4885 |
| US-20130030181-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | MCL1 4407/4885KDM4E 1385/4885ALDH1A1 164/4885 |
| US-20120225900-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, PC, ACACB | MCL1 4696/4885KDM4E 1533/4885ALDH1A1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.